ELMD
Electromed, Inc.29.88
+0.28+0.95%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q2 '26
Q&A affirms Brensocatib synergy
Q&A largely reaffirmed prepared remarks on bronchiectasis momentum and sales execution, with no walk-backs. Management positioned Brensocatib's blockbuster launch as an ally, raising disease awareness without impacting SmartVest—their Q4 grew in tandem. Rep productivity soared to $1.2 million annualized but will moderate to $1.0-1.1 million as headcount hits 61. New private payer contracts expand access by 2.9 million lives amid normal mix volatility. Buybacks remain opportunistic under $10 million authorization. Brensocatib helps, doesn't hurt. Analysts' payer and scaling probes got direct responses. Watch if awareness fuels durable rep output.
Key Stats
Market Cap
250.28MP/E (TTM)
31.79Basic EPS (TTM)
0.94Dividend Yield
0%Recent Filings
8-K
Record Q2 revenues, profits soar
Electromed posted record Q2 FY2026 results on February 10, 2026, with revenues up 16.3% to $18.9 million, operating income surging 42.4% to $3.6 million at 19.2% margin, and net income rising 40.3% to $2.8 million or $0.32 per diluted share. Homecare drove gains via more sales reps and higher productivity, while repurchasing $2.8 million in stock left $13.8 million cash, no debt. Growth streak hits 13 quarters.
10-Q
Q2 FY2026 results
Electromed posted Q2 FY2026 net revenues of $18.9M, up 16.3% y/y, driven by 18.4% homecare growth to $17.3M from more sales reps and higher output per rep, while hospital dipped 9.4%. Gross margin ticked to 78.4% from 77.7%; operating income jumped 42.4% y/y to $3.6M. Diluted EPS hit $0.32, up from $0.22, confirmed against 8.7M shares. Cash sits at $13.8M with $10M revolver fully available (no debt); OCF $3.2M less capex $0.9M yields FCF $2.3M (derived), offset by $3.8M buybacks. New BMO facility matures Dec 2026 at SOFR+1.75% with debt and coverage covenants. Revenue hinges on reimbursement shifts.
8-K
Electromed inks $10M facility
Electromed secured a $10M revolving credit facility from BMO Bank on December 16, 2025, maturing December 16, 2026, at one-month Term SOFR plus 1.75%, backed by all assets. It replaces the prior Choice Financial Group facility, funding capex, working capital, and corporate needs. Covenants demand 1.20x fixed charge coverage and 2.50x debt-to-EBITDA. New liquidity, yet tight terms bind.
8-K
Shareholders elect directors, ratify auditor
Electromed shareholders at the November 14, 2025 annual meeting elected eight directors, including James L. Cunniff with 5,022,691 for votes. They ratified RSM US LLP as auditors for fiscal 2026 and approved executive pay on an advisory basis. Board will hold annual say-on-pay votes. Strong support signals continuity.
10-Q
Q1 FY2026 results
Electromed posted Q1 FY2026 net revenues of $16.9M, up 15.1% y/y from $14.7M, fueled by homecare (up 12.7% to $14.9M), hospital (up 51.7% to $1.0M), and distributor gains; gross margin slipped to 78.1% from 78.3%. Operating income climbed 37.8% y/y to $2.7M, diluted EPS rose to $0.25 from $0.16 on 8.7M shares. Cash fell to $14.1M after $1.0M buybacks under a fresh $10M program, yet $2.5M revolver stands fully available sans debt. Operating cash flow slowed to $169K; free cash flow not disclosed in the 10-Q. Share repurchases signal confidence. Reimbursement shifts remain a risk.
CNMD
CONMED Corporation
39.20-1.12
DYNT
Dynatronics Corp.
0.04+0.00
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
ECOR
electroCore, Inc.
4.79+0.02
EMED
Electromedical Technologies, In
0.00+0.00
INSP
Inspire Medical Systems, Inc.
115.51-3.75
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
TCMD
Tactile Systems Technology, Inc
28.95+0.52
VMD
Viemed Healthcare, Inc.
7.26-0.11